One Hundred Years After ???Carcinoid???: Epidemiology of and Prognostic Factors for Neuroendocrine Tumors in 35,825 Cases in the United States, Journal of Clinical Oncology, vol.26, issue.18, pp.3063-72, 2008. ,
DOI : 10.1200/JCO.2007.15.4377
Multiple endocrine neoplasia type 1 (MEN1) and type 4 (MEN4), Molecular and Cellular Endocrinology, vol.386, issue.1-2, pp.2-15, 2014. ,
DOI : 10.1016/j.mce.2013.08.002
Clinical Practice Guidelines for Multiple Endocrine Neoplasia Type 1 (MEN1), The Journal of Clinical Endocrinology & Metabolism, vol.97, issue.9, 2012. ,
DOI : 10.1210/jc.2012-1230
Multiple endocrine neoplasia type 1 (MEN1): analysis of 1336 mutations reported in the first decade following identification of the gene, Human Mutation, vol.57, issue.1, 2008. ,
DOI : 10.1002/humu.20605
Molecular and Genetic Mechanisms of Tumorigenesis in Multiple Endocrine Neoplasia Type-1, Molecular Endocrinology, vol.15, issue.10, pp.1653-64, 2001. ,
DOI : 10.1210/mend.15.10.0717
Menin, the product of the MEN1 gene, is a nuclear protein, Proceedings of the National Academy of Sciences, vol.95, issue.4, pp.1630-1634, 1998. ,
DOI : 10.1073/pnas.95.4.1630
Menin interacts with the AP1 transcription factor JunD and represses JunD-activated transcription. Cell, pp.143-52, 1999. ,
The tumor suppressor protein menin interacts with NF-??B proteins and inhibits NF-??B-mediated transactivation, Oncogene, vol.20, issue.36, pp.4917-4942, 2001. ,
DOI : 10.1038/sj.onc.1204529
Inactivation of menin, a Smad3-interacting protein, blocks transforming growth factor type ?? signaling, Proceedings of the National Academy of Sciences, vol.98, issue.7, pp.3837-3879, 2001. ,
DOI : 10.1073/pnas.061358098
Menin-mediated Caspase 8 Expression in Suppressing Multiple Endocrine Neoplasia Type 1, Journal of Biological Chemistry, vol.282, issue.43, pp.31332-31372, 2007. ,
DOI : 10.1074/jbc.M609555200
Menin Associates with a Trithorax Family Histone Methyltransferase Complex and with the Hoxc8 Locus, Molecular Cell, vol.13, issue.4, pp.587-97, 2004. ,
DOI : 10.1016/S1097-2765(04)00081-4
Santé publique médecine légale, médecine du travail. Paris: Éd. Vernazobres-Grego, 2012. ,
Multiple endocrine neoplasia type 1 knockout mice develop parathyroid, pancreatic, pituitary and adrenal tumours with hypercalcaemia, hypophosphataemia and hypercorticosteronaemia, Endocrine Related Cancer, vol.16, issue.4, pp.1313-1340, 2009. ,
DOI : 10.1677/ERC-09-0082
Exploring the tumors of multiple endocrine neoplasia type 1 in mouse models for basic and preclinical studies, International Journal of Endocrine Oncology, vol.1, issue.2, pp.153-61, 2014. ,
DOI : 10.2217/ije.14.16
Autocrine growth inhibition by transforming growth factor ??-1 (TGF??-1) in human neuroendocrine tumour cells, Gut, vol.52, issue.9, pp.1308-1324, 2003. ,
DOI : 10.1136/gut.52.9.1308
Menin inactivation leads to loss of transforming growth factor beta inhibition of parathyroid cell proliferation and parathyroid hormone secretion. Cancer Res, pp.2222-2230, 2004. ,
Activin, TGF-?? and Menin in Pituitary Tumorigenesis, Adv Exp Med Biol, vol.668, pp.69-78, 2009. ,
DOI : 10.1007/978-1-4419-1664-8_7
Precursor Lesions in Patients With Multiple Endocrine Neoplasia Type 1--Associated Duodenal Gastrinomas, Gastroenterology, vol.128, issue.5, pp.1187-98, 2005. ,
DOI : 10.1053/j.gastro.2005.01.058
Conditional Inactivation of the Men1 Gene Leads to Pancreatic and Pituitary Tumorigenesis but Does Not Affect Normal Development of These Tissues, Molecular and Cellular Biology, vol.24, issue.8, pp.3125-3156, 2004. ,
DOI : 10.1128/MCB.24.8.3125-3131.2004
Thoracic and duodenopancreatic neuroendocrine tumors in multiple endocrine neoplasia type 1: natural history and function of menin in tumorigenesis, Endocrine Related Cancer, vol.21, issue.3, 2014. ,
DOI : 10.1530/ERC-13-0482
Age-related penetrance of endocrine tumours in multiple endocrine neoplasia type 1 (MEN1): a multicentre study of 258 gene carriers, Clinical Endocrinology, vol.243, issue.0, pp.613-635, 2007. ,
DOI : 10.1210/jc.86.12.5658
Risk Factors and Causes of Death in MEN1 Disease. A GTE (Groupe d???Etude des Tumeurs Endocrines) Cohort Study Among 758 Patients, World Journal of Surgery, vol.228, issue.2, pp.249-55, 2010. ,
DOI : 10.1007/s00268-009-0290-1
The origin of gut and pancreatic neuroendocrine (APUD) cells???the last word?, The Journal of Pathology, vol.387, issue.2, pp.117-125, 1998. ,
DOI : 10.1002/(SICI)1096-9896(1998100)186:2<117::AID-PATH152>3.0.CO;2-J
Chimères embryonnaires et développement du système nerveux. médecine/sciences, p.228, 1990. ,
The classification of carcinoid tumours. Lancet, Feb, vol.21, issue.7275, pp.238-247, 1963. ,
A 5-decade analysis of 13,715 carcinoid tumors. Cancer, pp.934-59, 2003. ,
Incidence and management of malignant digestive endocrine tumours in a well defined French population, Gut, vol.53, issue.4, 2004. ,
DOI : 10.1136/gut.2003.026401
Tumeurs endocrines thoraciques et digestives, 2008. ,
DOI : 10.1007/978-2-287-35574-5
World Health Organization, International Academy of Pathology, International Association for the Study of Lung Cancer, editors. Pathology and genetics of tumours of endocrine organs, 2004. ,
World Health Organization, International Agency for Research on Cancer, editors. WHO classification of tumours of the digestive system, 2010. ,
TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system. Virchows Arch, pp.395-401, 2006. ,
TNM staging of midgut and hindgut (neuro) endocrine tumors: a consensus proposal including a grading system, Virchows Archiv, vol.80, issue.Suppl 4, pp.757-62, 2007. ,
DOI : 10.1007/s00428-007-0452-1
Prospective Endoscopic Ultrasonographic Evaluation of the Frequency of Nonfunctioning Pancreaticoduodenal Endocrine Tumors in Patients with Multiple Endocrine Neoplasia Type 1, The American Journal of Gastroenterology, vol.24, issue.1 ,
DOI : 10.1002/bjs.4110
Epidemiology Data on 108 MEN 1 Patients From the GTE With Isolated Nonfunctioning Tumors of the Pancreas, Annals of Surgery, vol.243, issue.2, pp.265-72, 2006. ,
DOI : 10.1097/01.sla.0000197715.96762.68
ENETS Consensus Guidelines for the Management of Patients with Digestive Neuroendocrine Neoplasms: Functional Pancreatic Endocrine Tumor Syndromes, Neuroendocrinology, vol.95, issue.2, pp.98-119, 2012. ,
DOI : 10.1159/000335591
ENETS Consensus Guidelines for the Management of Patients with Gastroduodenal Neoplasms, Neuroendocrinology, vol.95, issue.2, pp.74-87, 2012. ,
DOI : 10.1159/000335595
International Agency for Research on Cancer, International Association for the Study of Lung Cancer, International Academy of Pathology. Pathology and genetics of tumours of the lung, pleura, thymus, and heart, 2004. ,
Bronchial carcinoids. Review of 124 cases, J Thorac Cardiovasc Surg, vol.89, issue.1, pp.8-17, 1985. ,
SEOM clinical guidelines for the diagnosis and treatment of gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs) 2014, Clinical and Translational Oncology, vol.7, issue.2, pp.1025-1059, 2014. ,
DOI : 10.1007/s12094-014-1214-6
ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Biochemical Markers, Neuroendocrinology, vol.90, issue.2, pp.194-202, 2009. ,
DOI : 10.1159/000225948
NANETS Consensus Guideline for the Diagnosis and Management of Neuroendocrine Tumors, Pancreas, vol.39, issue.6, 2010. ,
DOI : 10.1097/MPA.0b013e3181ec1380
Pituitary Disease in MEN Type 1 (MEN1): Data from the France-Belgium MEN1 Multicenter Study, Journal of Clinical Endocrinology & Metabolism, vol.87, issue.2, pp.457-65, 2002. ,
DOI : 10.1210/jc.87.2.457
Adrenal involvement in MEN1. Analysis of 715 cases from the Groupe d'etude des Tumeurs Endocrines database, European Journal of Endocrinology, vol.166, issue.2, pp.269-79 ,
DOI : 10.1530/EJE-11-0679
Meningiomas may be a component tumor of multiple endocrine neoplasia type 1. Clin Cancer Res Off J Am Assoc Cancer Res, Feb, vol.110, issue.3, pp.869-80, 2004. ,
Management of pancreatic neuroendocrine tumors in patients with MEN 1. Gland Surg, Feb, vol.4, issue.1, pp.63-71, 2015. ,
ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Radiological Examinations, Mallorca Consensus Conference participants, pp.167-83, 2009. ,
DOI : 10.1159/000184855
Gastroenteropancreatic Neuroendocrine Tumors: Role of Imaging in Diagnosis and Management, Radiology, vol.266, issue.1, pp.38-61, 2013. ,
DOI : 10.1148/radiol.12112512
Multiple Endocrine Neoplasia: Spectrum of Radiologic Appearances and Discussion of a Multitechnique Imaging Approach, RadioGraphics, vol.26, issue.2, pp.433-51, 2006. ,
DOI : 10.1148/rg.262055073
The Status of Neuroendocrine Tumor Imaging: From Darkness to Light?, Neuroendocrinology, vol.101, issue.1, pp.1-17, 2015. ,
DOI : 10.1159/000367850
Diffusion-weighted MR imaging in pancreatic endocrine tumors correlated with histopathologic characteristics, Journal of Magnetic Resonance Imaging, vol.113, issue.Suppl 1, pp.1071-1080, 2011. ,
DOI : 10.1002/jmri.22541
Endoscopic ultrasound is highly accurate and directs management in patients with neuroendocrine tumors of the pancreas, The American Journal of Gastroenterology, vol.111, issue.9, pp.2271-2278, 2000. ,
DOI : 10.1007/s002689900038
CT of pancreatic islet cell tumors. Radiology, Feb, vol.150, issue.2, pp.491-495, 1984. ,
CT of functioning tumors of the pancreas, American Journal of Roentgenology, vol.144, issue.1, pp.57-60, 1985. ,
DOI : 10.2214/ajr.144.1.57
Helical CT for the preoperative localization of islet cell tumors of the pancreas: value of arterial and parenchymal phase images., American Journal of Roentgenology, vol.165, issue.6, pp.1437-1446, 1995. ,
DOI : 10.2214/ajr.165.6.7484581
Nonfunctioning endocrine tumors of the pancreas: possibilities of spiral CT characterization, European Radiology, vol.11, issue.7, pp.1175-83, 2001. ,
DOI : 10.1007/s003300000714
Preoperative Detection of Pancreatic Insulinomas on Multiphasic Helical CT, American Journal of Roentgenology, vol.181, issue.3, 2003. ,
DOI : 10.2214/ajr.181.3.1810775
Detection of Small, Functional Islet Cell Tumors in the Pancreas: Selection of MR Imaging Sequences for Optimal Sensitivity, Radiology, vol.214, issue.2, pp.483-90, 2000. ,
DOI : 10.1148/radiology.214.2.r00fe32483
Neuroendocrine tumors of the pancreas: Spectrum of appearances on MRI, Journal of Magnetic Resonance Imaging, vol.19, issue.2, pp.141-149, 2000. ,
DOI : 10.1002/(SICI)1522-2586(200002)11:2<141::AID-JMRI10>3.0.CO;2-U
Noninvasive imaging of insulinomas and gastrinomas with endoscopic ultrasonography and somatostatin receptor scintigraphy. Surgery, pp.1134-1177, 1998. ,
Endosonography in decision making and management of gastrointestinal endocrine tumors, European Journal of Ultrasound, vol.10, issue.2-3, pp.2-3139, 1999. ,
DOI : 10.1016/S0929-8266(99)00054-3
Comparison of somatostatin receptor imaging, computed tomography and ultrasound in the clinical management of neuroendocrine gastro-entero-pancreatic tumours, European Journal of Nuclear Medicine and Molecular Imaging, vol.25, issue.10, pp.1396-403, 1998. ,
DOI : 10.1007/s002590050314
Imaging of neuroendocrine tumors: accuracy of helical CT versus SRS. Abdom Imaging, pp.696-702, 2004. ,
99mTc-EDDA/HYNIC-octreotate scintigraphy, an efficient method for the detection and staging of carcinoid tumours: results of 3??years??? experience, European Journal of Nuclear Medicine and Molecular Imaging, vol.19, issue.2, 2006. ,
DOI : 10.1007/s00259-006-0113-7
Diagnostic imaging of carcinoid metastases to the abdomen and pelvis, Med Sci Monit Int Med J Exp Clin Res, vol.10, pp.9-16, 2004. ,
MRI of Pancreatic Islet Cell Carcinoma, Journal of Computer Assisted Tomography, vol.17, issue.5, pp.735-775, 1993. ,
DOI : 10.1097/00004728-199309000-00013
Localization of neuroendocrine tumours with [111In] DTPA-octreotide scintigraphy (Octreoscan): a comparative study with CT and MR imaging, QJM, vol.91, issue.4, pp.295-301, 1998. ,
DOI : 10.1093/qjmed/91.4.295
Detection of Liver Metastases From Endocrine Tumors: A Prospective Comparison of Somatostatin Receptor Scintigraphy, Computed Tomography, and Magnetic Resonance Imaging, Journal of Clinical Oncology, vol.23, issue.1, pp.70-78, 2005. ,
DOI : 10.1200/JCO.2005.01.013
High Sensitivity of Diffusion-weighted MR Imaging for the Detection of Liver Metastases from Neuroendocrine Tumors: Comparison with T2-weighted and Dynamic Gadolinium-enhanced MR Imaging, Radiology, vol.268, issue.2, pp.390-399, 2013. ,
DOI : 10.1148/radiol.13121628
Magnetic resonance imaging versus endoscopic ultrasonography for the detection of pancreatic tumours in multiple endocrine neoplasia type 1. Dig Liver Dis Off J Ital Soc Gastroenterol Ital Assoc Study Liver, 2012. ,
Preoperative Assessment of the Pancreas in Multiple Endocrine Neoplasia Type 1, World Journal of Surgery, vol.19, issue.6, pp.1375-81 ,
DOI : 10.1007/s00268-012-1539-7
EUS is superior for detection of pancreatic lesions compared with standard imaging in patients with multiple endocrine neoplasia type 1, Gastrointestinal Endoscopy, vol.81, issue.1, pp.159-67, 2015. ,
DOI : 10.1016/j.gie.2014.09.037
Somatostatin receptor sst1-sst5 expression in normal and neoplastic human tissues using receptor autoradiography with subtype-selective ligands ,
Systemic Distribution of Somatostatin Receptor Subtypes in Human: An Immunohistochemical Study, Endocrine Journal, vol.52, issue.5, 2005. ,
DOI : 10.1507/endocrj.52.605
Somatostatin receptors, Biochimica et Biophysica Acta (BBA) - Biomembranes, vol.1616, issue.1, pp.1-84, 2003. ,
DOI : 10.1016/S0005-2736(03)00235-9
Immunohistochemical expression of somatostatin receptors in digestive endocrine tumours. Dig Liver Dis, pp.220-225, 2010. ,
Study, The Journal of Clinical Endocrinology & Metabolism, vol.88, issue.11, pp.5353-60, 2003. ,
DOI : 10.1210/jc.2002-021895
URL : https://hal.archives-ouvertes.fr/hal-00625303
Expression of somatostatin receptor types 1???5 in 81 cases of gastrointestinal and pancreatic endocrine tumors, Virchows Archiv, vol.440, issue.5, pp.461-75, 2002. ,
DOI : 10.1007/s00428-002-0609-x
Somatostatin receptor tissue distribution in lung neuroendocrine tumours: a clinicopathologic and immunohistochemical study of 218 'clinically aggressive' cases, Annals of Oncology, vol.21, issue.3, pp.548-55, 2010. ,
DOI : 10.1093/annonc/mdp334
Quantitative analysis of somatostatin receptor subtype (SSTR1-5) gene expression levels in somatotropinomas and non-functioning pituitary adenomas, European Journal of Endocrinology, vol.156, issue.1, pp.65-74, 2007. ,
DOI : 10.1530/eje.1.02313
Somatostatin receptor expression in adrenocortical tumors and effect of a new somatostatin analog SOM230 on hormone secretion in vitro and in ex vivo adrenal cells, Journal of Endocrinological Investigation, vol.177, issue.6, 2011. ,
DOI : 10.1007/BF03346721
Somatostatin receptor expression in non-medullary thyroid carcinomas. Horm Athens Greece, pp.290-296, 2012. ,
Somatostatin, cortistatin and their receptors in tumours, Molecular and Cellular Endocrinology, vol.286, issue.1-2, pp.219-248, 2008. ,
DOI : 10.1016/j.mce.2007.12.002
URL : https://hal.archives-ouvertes.fr/hal-00531971
Octreotide: Effective treatment for hyperparathyroidism? A prospective, randomized, controlled clinical trial, Surgery, vol.121, issue.6, 1997. ,
DOI : 10.1016/S0039-6060(97)90047-7
Somatostatin receptors in primary human breast cancer: quantitative analysis of mRNA for subtypes 1???5 and correlation with receptor protein expression and tumor pathology, Breast Cancer Research and Treatment, vol.49, issue.2, pp.175-86, 2005. ,
DOI : 10.1007/s10549-005-2414-0
Somatostatin Receptor in Human Hepatocellular Carcinomas: Biological, Patient and Tumor Characteristics, Digestive Surgery, vol.25, issue.1, pp.21-27, 2008. ,
DOI : 10.1159/000117819
Localization and mRNA expression of somatostatin receptor subtypes in human prostatic tissue and prostate cancer cell lines, Urologic Oncology: Seminars and Original Investigations, vol.7, issue.3, pp.91-99, 2002. ,
DOI : 10.1016/S1078-1439(01)00173-9
Somatostatin receptor subtype mRNA expression in human colorectal cancer and normal colonic mucosae, British Journal of Cancer, vol.75, issue.3, pp.360-366, 1997. ,
DOI : 10.1038/bjc.1997.59
Expression of Somatostatin Receptor Subtype 2 mRNA in Human Lymphoid Cells, Cellular Immunology, vol.181, issue.1, pp.44-53, 1997. ,
DOI : 10.1006/cimm.1997.1193
Differential expression of somatostatin receptor subtypes in human peripheral blood mononuclear cell subsets, European Journal of Endocrinology, vol.150, issue.4, pp.565-77, 2004. ,
DOI : 10.1530/eje.0.1500565
Vascular somatostatin receptors in synovium from patients with rheumatoid arthritis, European Journal of Pharmacology, vol.271, issue.2-3, pp.2-3371, 1994. ,
DOI : 10.1016/0014-2999(94)90796-X
Immunohistochemical localization of somatostatin receptor sst2A in sarcoid granulomas, European Journal of Clinical Investigation, vol.8, issue.1, pp.630-636, 1999. ,
DOI : 10.1007/s002590050297
111In-pentetreotide scintigraphy: procedure guidelines for tumour imaging, European Journal of Nuclear Medicine and Molecular Imaging, vol.37, issue.3B, pp.1441-1449, 2010. ,
DOI : 10.1007/s00259-010-1473-6
ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Somatostatin Receptor Imaging with <sup>111</sup>In-Pentetreotide, Neuroendocrinology, vol.90, issue.2, pp.184-193, 2009. ,
DOI : 10.1159/000225946
Somatostatin receptor scintigraphy with [111In-DTPA-d-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients, European Journal of Nuclear Medicine, vol.20, issue.8, pp.716-747, 1993. ,
DOI : 10.1007/BF00181765
Somatostatin receptor-mediated imaging and therapy: basic science, current knowledge, limitations and future perspectives, European Journal of Nuclear Medicine, vol.28, issue.9, pp.1421-1430, 2001. ,
DOI : 10.1007/s002590100502
Effective Doses in Radiology and Diagnostic Nuclear Medicine: A Catalog, Radiology, vol.248, issue.1, pp.254-63, 2008. ,
DOI : 10.1148/radiol.2481071451
Fluorodeoxyglucose-Positron Emission Tomography and Somatostatin Receptor Scintigraphy for High Ki67 (???10%) Well-Differentiated Endocrine Carcinoma Staging, The Journal of Clinical Endocrinology & Metabolism, vol.96, issue.3, pp.665-71, 2011. ,
DOI : 10.1210/jc.2010-2022
Octreoscan Versus FDG-PET for Neuroendocrine Tumor Staging: A Biological Approach, Annals of Surgical Oncology, vol.26, issue.6, pp.1-7, 2015. ,
DOI : 10.1245/s10434-015-4471-x
Functional imaging of neuroendocrine tumors with combined PET/CT using 68Ga-DOTATATE (DOTA-DPhe1,Tyr3- octreotate) and 18F-FDG. Cancer, pp.2447-55, 2008. ,
ENETS Consensus Guidelines for the Management of Patients with Liver and Other Distant Metastases from Neuroendocrine Neoplasms of Foregut, Midgut, Hindgut, and Unknown Primary, Neuroendocrinology, vol.95, issue.2, pp.157-76, 2012. ,
DOI : 10.1159/000335597
18F-Fluorodeoxyglucose Positron Emission Tomography Predicts Survival of Patients with Neuroendocrine Tumors, Clinical Cancer Research, vol.16, issue.3, pp.978-85, 2010. ,
DOI : 10.1158/1078-0432.CCR-09-1759
Chemistry of Aluminium, Gallium, Indium, and Thallium, 1993. ,
DOI : 10.1007/978-94-011-2170-5
68Ga-PET Radiopharmacy: A Generator-Based Alternative to 18F-Radiopharmacy, Ernst Scher Res Found Workshop, issue.62, pp.215-257, 2007. ,
DOI : 10.1007/978-3-540-49527-7_8
Radiopharmacie et médicaments radiopharmaceutiques. [Cachan]: Éd. Tec & doc-Lavoisier, 2012. ,
A phantom-based method to standardize dose-calibrators for new ??+-emitters, Nuclear Medicine Communications, vol.36, issue.2, pp.201-207, 2015. ,
DOI : 10.1097/MNM.0000000000000227
Past, present and future of 68Ge/68Ga generators, Appl Radiat Isot Data Instrum Methods Use Agric Ind Med. 2013, vol.76, pp.24-30 ,
Prospective of 68Ga-Radiopharmaceutical Development. Theranostics, pp.47-80, 2013. ,
Radiometal-Labelled Macrocyclic Chelator-Derivatised Somatostatin Analogue with Superb Tumour-Targeting Properties and Potential for Receptor-Mediated Internal Radiotherapy, Chemistry - A European Journal, vol.5, issue.7, pp.1974-81, 1999. ,
DOI : 10.1002/(SICI)1521-3765(19990702)5:7<1974::AID-CHEM1974>3.0.CO;2-X
Full automation of 68Ga labelling of DOTA-peptides including cation exchange prepurification, Applied Radiation and Isotopes, vol.68, issue.2, 2010. ,
DOI : 10.1016/j.apradiso.2009.10.006
Processing of Generator-Produced 68Ga for Medical Application, Journal of Nuclear Medicine, vol.48, issue.10, pp.1741-1749, 2007. ,
DOI : 10.2967/jnumed.107.040378
Guidance on current good radiopharmacy practice (cGRPP) for the small-scale preparation of radiopharmaceuticals ,
Tyr3)-octreotide(68Ga) injection. Pharmeuropa, pp.310-313, 2011. ,
Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use, European Journal of Nuclear Medicine and Molecular Imaging, vol.27, issue.3, pp.273-82, 2000. ,
DOI : 10.1007/s002590050034
68Ga-DOTANOC: a first compound for PET imaging with high affinity for somatostatin receptor subtypes 2 and 5, European Journal of Nuclear Medicine and Molecular Imaging, vol.28, issue.6, p.724, 2005. ,
DOI : 10.1007/s00259-004-1697-4
Procedure guidelines for PET/CT tumour imaging with 68Ga-DOTA-conjugated peptides: 68Ga-DOTA-TOC, 68Ga-DOTA-NOC, 68Ga-DOTA-TATE, European Journal of Nuclear Medicine and Molecular Imaging, vol.35, issue.4, pp.2004-2014, 2010. ,
DOI : 10.1007/s00259-010-1512-3
Dosimetry of [ 68 Ga]-labeled compounds, Appl Radiat Isot Data Instrum Methods Use Agric Ind Med. 2013, vol.76, pp.70-74 ,
68Ga-DOTA-TOC uptake in neuroendocrine tumour and healthy tissue: differentiation of physiological uptake and pathological processes in PET/CT, European Journal of Nuclear Medicine and Molecular Imaging, vol.39, issue.4, pp.514-537 ,
DOI : 10.1007/s00259-012-2309-3
Semiquantitative Analysis and Characterization of Physiological Biodistribution of 68Ga-DOTA-TATE PET/CT, Clinical Nuclear Medicine, vol.37, issue.11, pp.1052-1059, 2012. ,
DOI : 10.1097/RLU.0b013e31825b2555
Biodistribution of the Ga-68 labeled somatostatin analogue DOTA-NOC in patients with neuroendocrine tumors: characterization of uptake in normal organs and tumor lesions, Q J Nucl Med Mol Imaging Off Publ Ital Assoc Nucl Med AIMN Int Assoc Radiopharmacol IAR Sect Soc Radiopharm Chem Biol. Feb, vol.54, issue.1, pp.61-68, 2010. ,
Ga DOTATATE PET/CT: Clinical Utility, Normal Patterns, Pearls, and Pitfalls in Interpretation, RadioGraphics, vol.35, issue.2, pp.500-516, 2015. ,
DOI : 10.1148/rg.352140164
Detection of pancreatic neuroendocrine tumors (PNET) using semi-quantitative [68Ga]DOTATOC PET in combination with multiphase contrast-enhanced CT, Q J Nucl Med Mol Imaging Off Publ Ital Assoc Nucl Med AIMN Int Assoc Radiopharmacol IAR Sect Soc Radiopharm Chem Biol, vol.58, issue.3, pp.310-318, 2014. ,
Splenunculus Masquerading as a Neuroendocrine Tumor of the Pancreatic Allograft in a Kidney-Pancreas Recipient, Transplantation Journal, vol.96, issue.8, pp.59-62, 2013. ,
DOI : 10.1097/TP.0b013e3182a80c67
Biokinetics and imaging with the somatostatin receptor PET radioligand 68Ga-DOTATOC: preliminary data, European Journal of Nuclear Medicine, vol.28, issue.12, pp.1751-1758, 2001. ,
DOI : 10.1007/s002590100639
Comparison of 68Ga-DOTATOC PET and 111In-DTPAOC (Octreoscan) SPECT in patients with neuroendocrine tumours, European Journal of Nuclear Medicine and Molecular Imaging, vol.30, issue.2, pp.1617-1643, 2007. ,
DOI : 10.1007/s00259-007-0450-1
68Ga-DOTA-Tyr3-Octreotide PET in Neuroendocrine Tumors: Comparison with Somatostatin Receptor Scintigraphy and CT, Journal of Nuclear Medicine, vol.48, issue.4, pp.508-526, 2007. ,
DOI : 10.2967/jnumed.106.035667
Bone Metastases in Patients with Neuroendocrine Tumor: 68Ga-DOTA-Tyr3-Octreotide PET in Comparison to CT and Bone Scintigraphy, Journal of Nuclear Medicine, vol.50, issue.8, 2009. ,
DOI : 10.2967/jnumed.108.060236
Ga-68 DOTATOC PET, Endoscopic Ultrasonography, and Multidetector CT in the Diagnosis of Duodenopancreatic Neuroendocrine Tumors, Clinical Nuclear Medicine, vol.35, issue.5, 2010. ,
DOI : 10.1097/RLU.0b013e3181d6677c
Role of (68)Ga-DOTATOC PET-CT in the diagnosis and staging of pancreatic neuroendocrine tumours, Eur Radiol, 2011. ,
Evaluation of the potential of PET-MRI fusion for detection of liver metastases in patients with neuroendocrine tumours, European Radiology, vol.37, issue.Suppl 1, pp.458-67, 2012. ,
DOI : 10.1007/s00330-011-2266-4
Staging of neuroendocrine tumours: comparison of [68Ga]DOTATOC multiphase PET/CT and whole-body MRI, Cancer Imaging, vol.13, issue.1, pp.63-72, 2013. ,
DOI : 10.1102/1470-7330.2013.0007
68Ga-DOTA-Tyr3-Octreotide PET for Assessing Response to Somatostatin-Receptor-Mediated Radionuclide Therapy, Journal of Nuclear Medicine, vol.50, issue.9, pp.1427-1461, 2009. ,
DOI : 10.2967/jnumed.108.053421
Peptide receptor radionuclide therapy of neuroendocrine tumors with 90Y-DOTATOC: Is treatment response predictable by pre-therapeutic uptake of 68Ga-DOTATOC? Diagn Interv Imaging, 2014. ,
SUV of [68Ga]DOTATOC-PET/CT Predicts Response Probability of PRRT in Neuroendocrine Tumors, Molecular Imaging and Biology, vol.36, issue.3, pp.1-6, 2014. ,
DOI : 10.1007/s11307-014-0795-3
Quantitative and Qualitative Intrapatient Comparison of 68Ga-DOTATOC and 68Ga-DOTATATE: Net Uptake Rate for Accurate Quantification, Journal of Nuclear Medicine, vol.55, issue.2, pp.204-214 ,
DOI : 10.2967/jnumed.113.126177
Impact of Ga-68 DOTATOC PET/CT on the diagnosis and treatment of patients with multiple endocrine neoplasia, Annals of Nuclear Medicine, vol.5, issue.9, pp.738-781, 2012. ,
DOI : 10.1007/s12149-012-0634-z
Accuracy of 68Ga DOTANOC PET/CT Imaging in Patients With Multiple Endocrine Neoplasia Syndromes, Clinical Nuclear Medicine, vol.40, issue.7, 2015. ,
DOI : 10.1097/RLU.0000000000000775
Results of 68Gallium-DOTATATE PET/CT Scanning in Patients with Multiple Endocrine Neoplasia Type 1, Journal of the American College of Surgeons, vol.221, issue.2, pp.509-526, 2015. ,
DOI : 10.1016/j.jamcollsurg.2015.04.005
Abstract, Radiology and Oncology, vol.48, issue.4, pp.339-386, 2014. ,
DOI : 10.2478/raon-2014-0018
Additional information gained by positron emission tomography with (68)Ga-DOTATOC for suspected unknown primary or recurrent neuroendocrine tumors, Ann Nucl Med, 2015. ,
Detection of unknown primary neuroendocrine tumours (CUP-NET) using 68Ga-DOTA-NOC receptor PET/CT, European Journal of Nuclear Medicine and Molecular Imaging, vol.35, issue.Suppl 1, pp.67-77, 2010. ,
DOI : 10.1007/s00259-009-1205-y
A retrospective comparison between 68Ga-DOTA-TOC PET/CT and 18F-DOPA PET/CT in patients with extra-adrenal paraganglioma, European Journal of Nuclear Medicine and Molecular Imaging, vol.54, issue.12, pp.1800-1808, 2013. ,
DOI : 10.1007/s00259-013-2548-y
Ga-DOTATOC PET/CT provides accurate tumour extent in patients with extraadrenal paraganglioma compared to (123)I-MIBG SPECT/CT, Eur J Nucl Med Mol Imaging. 2015, vol.6842, issue.1, pp.33-41 ,
68Ga-DOTATATE PET in neuroectodermal tumours: First experience, Nuclear Medicine Communications, vol.28, issue.5, pp.359-63, 2007. ,
DOI : 10.1097/MNM.0b013e32808ea0b0
Detection of cranial meningiomas: comparison of 68Ga-DOTATOC PET/CT and contrast-enhanced MRI, European Journal of Nuclear Medicine and Molecular Imaging, vol.47, issue.1, pp.1409-1424, 2012. ,
DOI : 10.1007/s00259-012-2155-3
Contribution of 68Ga-DOTATOC PET/CT to Target Volume Delineation of Skull Base Meningiomas Treated With Stereotactic Radiation Therapy, International Journal of Radiation Oncology*Biology*Physics, vol.85, issue.1, pp.68-73, 2013. ,
DOI : 10.1016/j.ijrobp.2012.03.021
Surgical Treatment of Hyperparathyroidism in Patients With Multiple Endocrine Neoplasia Type 1, Archives of Surgery, vol.140, issue.4, pp.374-82, 1960. ,
DOI : 10.1001/archsurg.140.4.374
Preoperative Localizing Studies for Initial Parathyroidectomy in MEN1 Syndrome: Is There Any Benefit?, World Journal of Surgery, vol.32, issue.6, pp.1368-74 ,
DOI : 10.1007/s00268-012-1451-1
Value of 18-F-FDG PET/CT and CT in the Diagnosis of Indeterminate Adrenal Masses, International Journal of Endocrinology, vol.10, p.213875, 2015. ,
DOI : 10.2214/ajr.08.1431
Molecular imaging of adrenal neoplasms, Journal of Surgical Oncology, vol.22, issue.5, pp.532-574, 2012. ,
DOI : 10.1002/jso.23162
F-FDG PET/CT of Adrenal Lesions, American Journal of Roentgenology, vol.203, issue.2, pp.245-52, 2014. ,
DOI : 10.2214/AJR.13.11793
Efficacy of iodine-131 6beta-methyl-iodo-19-norcholesterol scintigraphy and computed tomography in patients with primary aldosteronism, Eur J Nucl Med, vol.26, issue.10, pp.1326-1358, 1999. ,
Modern Nuclear Imaging for Paragangliomas: Beyond SPECT, Journal of Nuclear Medicine, vol.53, issue.2, pp.264-74 ,
DOI : 10.2967/jnumed.111.098152
EANM 2012 guidelines for radionuclide imaging of phaeochromocytoma and paraganglioma, European Journal of Nuclear Medicine and Molecular Imaging, vol.72, issue.Suppl 1, pp.1977-95, 2012. ,
DOI : 10.1007/s00259-012-2215-8
ENETS Consensus Guidelines for the Management of Patients with Digestive Neuroendocrine Neoplasms of the Digestive System: Well-Differentiated Pancreatic Non-Functioning Tumors, Neuroendocrinology, vol.95, issue.2, pp.120-154, 2012. ,
DOI : 10.1159/000335587
Everolimus for Advanced Pancreatic Neuroendocrine Tumors, New England Journal of Medicine, vol.364, issue.6, pp.514-537, 2011. ,
DOI : 10.1056/NEJMoa1009290
Sunitinib Malate for the Treatment of Pancreatic Neuroendocrine Tumors, New England Journal of Medicine, vol.364, issue.6, pp.501-514, 2011. ,
DOI : 10.1056/NEJMoa1003825
ENETS Consensus Guidelines for the Management of Bone and Lung Metastases from Neuroendocrine Tumors, Neuroendocrinology, vol.91, issue.4, pp.341-50, 2010. ,
DOI : 10.1159/000287255
Poorly-Differentiated Endocrine Carcinomas of Midgut and Hindgut Origin, Neuroendocrinology, vol.87, issue.1, pp.40-46, 2008. ,
DOI : 10.1159/000109976
The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours, European Journal of Nuclear Medicine and Molecular Imaging, vol.20, issue.Suppl 1, pp.800-816, 2013. ,
DOI : 10.1007/s00259-012-2330-6
Y-DOTA]-TOC in Metastasized Neuroendocrine Cancers, Journal of Clinical Oncology, vol.29, issue.17, pp.2416-2439, 2011. ,
DOI : 10.1200/JCO.2010.33.7873
Nuclear medicine techniques for the imaging and treatment of neuroendocrine tumours, Endocrine Related Cancer, vol.18, issue.S1, pp.27-51, 2011. ,
DOI : 10.1530/ERC-10-0282
]Octreotate: Toxicity, Efficacy, and Survival, Journal of Clinical Oncology, vol.26, issue.13, pp.2124-2154, 2008. ,
DOI : 10.1200/JCO.2007.15.2553
ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Peptide Receptor Radionuclide Therapy with Radiolabeled Somatostatin Analogs, Neuroendocrinology, vol.90, issue.2, pp.220-226, 2009. ,
DOI : 10.1159/000225951
68Ga-PET: a powerful generator-based alternative to cyclotron-based PET radiopharmaceuticals, Contrast Media & Molecular Imaging, vol.22, issue.2, pp.53-63, 2008. ,
DOI : 10.1002/cmmi.232
Ga Bioconjugates with High Specific Radioactivity, Bioconjugate Chemistry, vol.15, issue.3, pp.554-60, 2004. ,
DOI : 10.1021/bc030078f
Robust labeling and comparative preclinical characterization of DOTA-TOC and DOTA-TATE, Nuclear Medicine and Biology, vol.39, issue.5, pp.628-667 ,
DOI : 10.1016/j.nucmedbio.2011.12.010
Evaluation of Positron Emission Tomography Imaging Using [68Ga]-DOTA-D Phe1-Tyr3-Octreotide in Comparison to [111In]-DTPAOC SPECT. First Results in Patients with Neuroendocrine Tumors, Molecular Imaging & Biology, vol.5, issue.1, pp.42-50, 2003. ,
DOI : 10.1016/S1536-1632(03)00038-6
Comparison of diagnostic accuracy of (111)In-pentetreotide SPECT and (68)Ga-DOTATOC PET/CT: A lesion-by-lesion analysis in patients with metastatic neuroendocrine tumours, Eur Radiol, 2015. ,
Normal Uptake of 68Ga-DOTA-TOC by the Pancreas Uncinate Process Mimicking Malignancy at Somatostatin Receptor PET, Clinical Nuclear Medicine, vol.37, issue.4, pp.362-367 ,
DOI : 10.1097/RLU.0b013e3182485110
Indium-111 Pentetreotide Uptake By Pancreatic Polypeptide Cell Hyperplasia, Pancreas, vol.35, issue.4, pp.372-377, 2007. ,
DOI : 10.1097/mpa.0b013e31811ea2a2
Impact of Ga-68 DOTATOC PET/CT on the diagnosis and treatment of patients with multiple endocrine neoplasia, Annals of Nuclear Medicine, vol.5, issue.9, pp.738-781, 2012. ,
DOI : 10.1007/s12149-012-0634-z
Somatostatin receptor based PET/CT imaging with 68Ga-DOTA-Nal3-Octreotide for localisation of clinically and biochemically suspected insulinoma, Q J Nucl Med Mol Imaging Off Publ Ital Assoc Nucl Med AIMN Int Assoc Radiopharmacol IAR Sect Soc Of, 2014. ,
18F-FDOPA PET/CT imaging of insulinoma revisited, European Journal of Nuclear Medicine and Molecular Imaging, vol.33, issue.3, pp.409-427 ,
DOI : 10.1007/s00259-014-2943-z
Peptide Receptors as Molecular Targets for Cancer Diagnosis and Therapy, Endocrine Reviews, vol.24, issue.4, pp.389-427, 2003. ,
DOI : 10.1210/er.2002-0007
Localization of Hidden Insulinomas with 68Ga-DOTA-Exendin-4 PET/CT: A Pilot Study, Journal of Nuclear Medicine, vol.56, issue.7, 2015. ,
DOI : 10.2967/jnumed.115.157768
2009 EANM parathyroid guidelines, EANM parathyroid guidelines, pp.1201-1217, 2009. ,
DOI : 10.1007/s00259-009-1131-z
Phospholipid/Ca2+-dependent Protein Kinase Activity in Human Parathyroid Adenoma., Endocrinologia Japonica, vol.34, issue.6, 1987. ,
DOI : 10.1507/endocrj1954.34.965
18F-Fluorocholine PET/CT for localization of hyperfunctioning parathyroid tissue in primary hyperparathyroidism: a pilot study, European Journal of Nuclear Medicine and Molecular Imaging, vol.248, issue.6, pp.2083-2092, 2014. ,
DOI : 10.1007/s00259-014-2837-0
Are contrast media required for (68)Ga-DOTATOC PET/CT in patients with neuroendocrine tumours of the abdomen?, European Radiology, vol.37, issue.4, pp.938-984 ,
DOI : 10.1007/s00330-011-2328-7
Detection of neuroendocrine tumours in the small intestines using contrast-enhanced multiphase Ga-68 DOTATOC PET/CT: the potential role of arterial hyperperfusion, Radiology and Oncology, vol.48, issue.2, pp.120-126, 2014. ,
DOI : 10.2478/raon-2014-0012
68Ga-DOTATOC PET/CT of Neuroendocrine Tumors: Spotlight on the CT Phases of a Triple-Phase Protocol, Journal of Nuclear Medicine, vol.52, issue.5, pp.697-704, 2011. ,
DOI : 10.2967/jnumed.110.083741
Dosimétrie des explorations diagnostiques en médecine nucléaire. SFPM, pp.19-2001, 2001. ,
Cost comparison of 111In-DTPA-octreotide scintigraphy and 68Ga-DOTATOC PET/CT for staging enteropancreatic neuroendocrine tumours, European Journal of Nuclear Medicine and Molecular Imaging, vol.13, issue.3, pp.72-82 ,
DOI : 10.1007/s00259-011-1935-5
The Impact of 68Ga-DOTATOC Positron Emission Tomography/Computed Tomography on the Multimodal Management of Patients With Neuroendocrine Tumors, Annals of Surgery, vol.252, issue.5, pp.850-856, 2010. ,
DOI : 10.1097/SLA.0b013e3181fd37e8
PET tracers for somatostatin receptor imaging of neuroendocrine tumors: current status and review of the literature, Future Oncology, vol.10, issue.14, pp.2259-77, 2014. ,
DOI : 10.2217/fon.14.139
64Cu-DOTATATE PET for Neuroendocrine Tumors: A Prospective Head-to-Head Comparison with 111In-DTPA-Octreotide in 112 Patients, Journal of Nuclear Medicine, vol.56, issue.6, pp.847-54, 2015. ,
DOI : 10.2967/jnumed.115.156539
Gluc- Lys([18F]FP)-TOCA PET in patients with SSTR-positive tumors: biodistribution and diagnostic evaluation compared with [111In]DTPA-octreotide, 2006. ,
Can Fluorodihydroxyphenylalanine PET Replace Somatostatin Receptor Scintigraphy in Patients with Digestive Endocrine Tumors?, J Nucl Med, vol.47, issue.9, pp.1455-62, 2006. ,
Impact of Fluorodihydroxyphenylalanine-(18F) Positron Emission Tomography on Management of Adult Patients with Documented or Occult Digestive Endocrine Tumors, The Journal of Clinical Endocrinology & Metabolism, vol.94, issue.4, 2009. ,
DOI : 10.1210/jc.2008-1349